// App-Quantinova.ai

P078 : Updated Safety Of Cladribine Tablets In The Treatment Of Patients With Multiple Sclerosis: Integrated Safety Analysis And Post-approval Data

Researchers

Presenter

  • S. Cook

Principal Investigators

  • G. Giovannoni

  • T. P. Leist

  • G. Comi

  • S. Syed

  • A. Nolting

  • D. Damian

  • R. Schick

Medical Centers

  • Rutgers-New Jersey Medical School, Newark, NJ

  • Queen Mary University of London and Blizard Institute Barts and The London School of Medicine and Dentistry London United Kingdom

  • Division of Clinical Neuroimmunology, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA

  • 2Department of Neurology and Institute of Experimental Neurology, Università Vita-Salute San Raffaele Milan Italy

  • EMD Serono, Inc, Billerica, MA

  • Merck KGaA, Darmstadt, Germany

Locations

  • United States

  • United Kingdom

  • Italy

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Placebo Control

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved